The Scottish Medicines Consortium (SMC) has accepted rotigotine (Neupro™) for use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome (RLS) in adults. It should only be used in patients with a baseline score of 15 points or more on the International Restless Legs Scale (IRLS).

Compared with placebo, rotigotine was associated with improvements on a patient-administered scale based on the core clinical features of the syndrome and on the incidence of periodic limb movements during time in bed.

Other dopamine agonists licensed for use in RLS are available at a lower cost.